Back to Trial

Oracle Runs

Oracle findings and outcome history for CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma (NCT05257590).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 8:22 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

An exact-trial conference abstract for NCT05257590 reports the combo “demonstrated clinical activity,” had a favorable safety profile, and “support[s] further development,” which is clear positive framing for this study. ClinicalTrials.gov still shows the study as recruiting, so this appears to be an interim positive public readout.

Sources
Web Searchs3.amazonaws.com8/1/24
BT24 Abstracts PDF: CVM-1118 with nivolumab in unresectable advanced HCC—A phase IIa study

For NCT05257590, the abstract concludes CVM-1118+nivolumab “demonstrated clinical activity” in advanced HCC and that the data “support further development” of the combination.

View source
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov: NCT05257590 study details

ClinicalTrials.gov lists NCT05257590 as a Phase 2 study of CVM-1118 plus nivolumab in unresectable advanced hepatocellular carcinoma and shows the trial as recruiting.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted84% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

An exact-trial conference abstract for NCT05257590 reports the combo “demonstrated clinical activity,” had a favorable safety profile, and “support[s] further development,” which is clear positive framing for this study. ClinicalTrials.gov still shows the study as recruiting, so this appears to be an interim positive public readout.

Found Apr 1, 2026, 8:22 PMOutcome date Aug 1, 2024, 12:00 AMReviewed Apr 1, 2026, 8:24 PM
Web Searchs3.amazonaws.comAug 1, 2024, 12:00 AM
BT24 Abstracts PDF: CVM-1118 with nivolumab in unresectable advanced HCC—A phase IIa study
For NCT05257590, the abstract concludes CVM-1118+nivolumab “demonstrated clinical activity” in advanced HCC and that the data “support further development” of the combination.
ClinicalTrialsclinicaltrials.gov
ClinicalTrials.gov: NCT05257590 study details
ClinicalTrials.gov lists NCT05257590 as a Phase 2 study of CVM-1118 plus nivolumab in unresectable advanced hepatocellular carcinoma and shows the trial as recruiting.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 8:24 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)84% confidenceReviewed Apr 1, 2026, 8:24 PM

An exact-trial conference abstract for NCT05257590 reports the combo “demonstrated clinical activity,” had a favorable safety profile, and “support[s] further development,” which is clear positive framing for this study. ClinicalTrials.gov still shows the study as recruiting, so this appears to be an interim positive public readout.